- Home
- IRD vs SNAL Comparison
IRD vs SNAL Comparison
Compare IRD & SNAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRD
- SNAL
- Stock Information
- Founded
- IRD 2018
- SNAL 2000
- Country
- IRD United States
- SNAL United States
- Employees
- IRD N/A
- SNAL N/A
- Industry
- IRD
- SNAL Computer Software: Prepackaged Software
- Sector
- IRD
- SNAL Technology
- Exchange
- IRD NYSE
- SNAL Nasdaq
- Market Cap
- IRD 38.8M
- SNAL 40.0M
- IPO Year
- IRD N/A
- SNAL 2022
- Fundamental
- Price
- IRD $0.99
- SNAL $1.04
- Analyst Decision
- IRD Strong Buy
- SNAL
- Analyst Count
- IRD 2
- SNAL 0
- Target Price
- IRD $7.00
- SNAL N/A
- AVG Volume (30 Days)
- IRD 206.9K
- SNAL 44.3K
- Earning Date
- IRD 05-15-2025
- SNAL 05-19-2025
- Dividend Yield
- IRD N/A
- SNAL N/A
- EPS Growth
- IRD N/A
- SNAL N/A
- EPS
- IRD N/A
- SNAL 0.05
- Revenue
- IRD $10,992,000.00
- SNAL $84,467,047.00
- Revenue This Year
- IRD $22.00
- SNAL $21.96
- Revenue Next Year
- IRD $100.89
- SNAL $22.77
- P/E Ratio
- IRD N/A
- SNAL $19.88
- Revenue Growth
- IRD N/A
- SNAL 38.69
- 52 Week Low
- IRD $0.65
- SNAL $0.52
- 52 Week High
- IRD $2.18
- SNAL $3.42
- Technical
- Relative Strength Index (RSI)
- IRD N/A
- SNAL 47.75
- Support Level
- IRD N/A
- SNAL $0.98
- Resistance Level
- IRD N/A
- SNAL $1.08
- Average True Range (ATR)
- IRD 0.00
- SNAL 0.08
- MACD
- IRD 0.00
- SNAL 0.02
- Stochastic Oscillator
- IRD 0.00
- SNAL 59.26
About IRD OPUS GENETICS INC
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA), and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.
About SNAL Snail Inc.
Snail Inc is an independent developer and publisher of interactive digital entertainment for consumers around the world, with a portfolio of premium games designed for use on a variety of platforms, including consoles, PC's, and mobile devices. The geographic presence of the company is in the United States and the International market, where the majority of its revenue comes from the United States.